Company / Shareholders' Equity
Astria Therapeutics, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$319.3M
FY2024
5-year range
$40.7M / $319.3M
FY2020-FY2024
Trend
+31.3%
vs FY2023
Sector context
#125 of 213
Health Care
What the data says
At $319M, Astria Therapeutics, Inc.'s shareholders' equity ranks #125 of 213 in the Health Care sector. Shareholders' Equity has increased for 7 consecutive years, from $12M in FY2017 to $319M in FY2024.
Based on SEC 10-K filings.
$319M in FY2024 with a 5-year CAGR of +55.0%.
Improved from $221M to $319M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +37.7%
- 5-Year CAGR
- +55.0%
- 10-Year CAGR
- -
Sector benchmark
#125 of 213 in Health CareTop 59% of 213This company $319.3M Sector average $2.5B
▼
-87.5% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s shareholders' equity has grown for 7 consecutive years.
- 5-year CAGR of +55.0%, indicating consistent growth.
- In FY2024, shareholders' equity increased 31.3% year-over-year.
- Ranks #125 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $319.3M | +31.3% |
| FY2023 | $243.1M | +9.9% |
| FY2022 | $221.2M | +80.9% |
| FY2021 | $122.3M | +200.7% |
| FY2020 | $40.7M | +13.9% |
| FY2019 | $35.7M | +2.2% |
| FY2018 | $34.9M | +196.3% |
| FY2017 | $11.8M | -59.5% |
| FY2016 | $29.1M | -42.4% |
| FY2015 | $50.5M | +169.1% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026